Whah Wonder
an interpretive portrait in wool of Jimi Hendrix

In the words of the designer Ned Baker:

I am lifelong student and admirer of 60’s-70’s music - particularly the explosive evolution of the electric guitar and the iconic imagery of the albums and posters from that era.

This rug is a tribute to this period of social unrest and the breaking of barriers AND new ground. The contrast of bold design against a plainer, more organic background shows how the music and sentiments of the time contrasted with what was heretofore considered “normal.”

Rustigian’s:
AN EXTRAORDINARY RUG STORE

Phase I Cancer Immunotherapy Trial at Roger Williams Shows Promising Results

PROVIDENCE – Researchers at the Roger Williams Cancer Center have shown encouraging results from a recently completed trial involving immunotherapy for cancer patients. Final results from the “Hepatic Immunotherapy for Metastases [HITM] Phase 1 trial [NCT01373047]” for patients with stage IV colon cancer and liver metastases were recently presented at the 2014 Society of Surgical Oncology [SSO] meeting. The SSO funded the study. In six patients whose disease had been progressing on standard therapy, genetically-modified T cells were delivered directly into the liver’s arterial circulation. The treatment was shown to be well tolerated.

In several patients, the team – which included DR. STEVEN KATZ, DR. RICHARD JUNGHANS, and DR. N. JOSEPH ESPAT – reported encouraging evidence of clinical activity. Tumor markers decreased and biopsies of liver tumors demonstrated evidence of tumor cell killing in patients who had been treated with multiple lines of conventional chemotherapy. One patient has survived more than 12 months following treatment.

“This is an important advance for the treatment of liver metastases,” said Dr. Katz, the principal investigator for the HITM trial. “We are combining a potent immunotherapeutic tool with a powerful and rational delivery strategy to minimize side effects and optimize clinical effect. Our platform is still at an early stage and we look forward to future clinical trials to define the best immunotherapy strategy for liver metastases.”

Ongoing work in the Roger Williams Immunotherapy Laboratory, funded by the NIH, will guide the design of future trials.